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Involving Metabolism and Transport: 
Methodology, Pitfalls, and Interpretation
Aleksi Tornio1,2, Anne M. Filppula1,2, Mikko Niemi1,2 and Janne T. Backman1,2,*
Many drug–drug interactions (DDIs) are based on alterations of the plasma concentrations of a victim drug due to 
another drug causing inhibition and/or induction of the metabolism or transporter- mediated disposition of the victim 
drug. In the worst case, such interactions cause more than tenfold increases or decreases in victim drug exposure, 
with potentially life- threatening consequences. There has been tremendous progress in the predictability and 
modeling of DDIs. Accordingly, the combination of modeling approaches and clinical studies is the current mainstay 
in evaluation of the pharmacokinetic DDI risks of drugs. In this paper, we focus on the methodology of clinical 
studies on DDIs involving drug metabolism or transport. We specifically present considerations related to general 
DDI study designs, recommended enzyme and transporter index substrates and inhibitors, pharmacogenetic 
perspectives, index drug cocktails, endogenous substrates, limited sampling strategies, physiologically-based 
pharmacokinetic modeling, complex DDIs, methodological pitfalls, and interpretation of DDI information.
Unintentional and mismanaged drug–drug interactions (DDIs) 
are a common reason for preventable adverse events.1 As the popu-
lation is aging and polypharmacotherapy is becoming progressively 
more common, there is an increased likelihood of DDIs that can 
inadvertently lead to exaggeration of adverse effects or—in some 
cases—loss of drug efficacy. As these kind of events cannot be pre-
vented without recognizing the need to adjust medications accord-
ing to DDI risks, there is a need for carefully planned preclinical 
and clinical DDI studies during drug development, and typically 
also after marketing approval, as well as for modeling studies, da-
tabases, and clinical decision support systems that can be easily im-
plemented and used to improve clinical decision making.
In the past, extreme safety concerns caused by DDIs have led to 
multiple market withdrawals, such as those of mibefradil, terfena-
dine, cisapride, and cerivastatin in the late 1990s and early 2000s. 
Due to such unfortunate incidents and the rapid accumulation of 
scientific knowledge that has improved the understanding of DDI 
mechanisms and awareness of DDI risks, regulatory agencies have 
frequently updated their guidances on drug interaction studies. For 
example, the last clinical drug interaction studies guidance by the 
US Food and Drug Administration (FDA) was published in 2017 
and that by the European Medicines Agency (EMA) is currently 
being revised.2,3 Even though these guidelines are directed for stud-
ies performed for drugs under development, their concepts can be 
applied to drugs on the market as well.
The above developments have led to marked advances in the 
conduct of DDI studies during drug development. As a result, 
the number of drug withdrawals due to DDIs has dramatically de-
creased and detailed knowledge on mechanisms, clinical relevance, 
and management of DDIs mediated by inhibition or induction 
of cytochrome P450 (CYPs) enzymes, some other enzymes, and 
key transporters are, in most cases, available already at the time of 
marketing approval. For example, among the 34 drugs approved 
by the FDA in 2017, 5 had been identified as sensitive substrates 
of CYP3A or organic anion-transporting polypeptide (OATP) 
1B1, and 3 had been considered as strong inhibitors of CYP3A, 
OATP1B1, or breast cancer resistance protein (BCRP), whereas 
no strong inducers had been identified.4
A major proportion of harmful drug interactions is based on 
alterations of the plasma concentrations of the victim drug due 
to the perpetrator drug causing a change in the metabolism or 
transporter- mediated disposition of the victim drug. Inhibition 
of drug metabolism or transporter- dependent elimination in 
most cases leads to elevated concentrations of the victim drug, 
whereas induction increases metabolic elimination, decreasing 
the concentrations of the victim. In the worst case, such inter-
actions can lead to several hundred- fold variations in drug expo-
sure.5,6 During the past decade, several review articles have been 
published focusing on various specific aspects related to clinical 
DDI studies.7–10 In this paper, we present an overview of the 
basic methodology of clinical DDI studies that can be used when 
investigating a specific drug as a victim or perpetrator of phar-
macokinetic DDIs mediated by inhibition or induction of drug- 
metabolizing enzymes and/or transporters, with an attempt to 
pinpoint specific considerations that we have found important 
on the basis of our own experience in clinical DDI studies. As 
much of the methodology described in regulatory guidance is 
focused on studies carried out during drug development, we 
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extend the review beyond the regulatory guidance, highlighting 
certain specific questions related to complex DDIs, pharmaco-
genetics, methodological pitfalls, and interpretation of DDI 
information.
DESIGN OF CLINICAL DDI STUDIES
General considerations of clinical DDI study design
With regard to pharmacokinetic DDIs, the study hypotheses and 
objectives essentially define the most suitable study design. Based 
on prior information, an evaluation of interaction risk is usually 
carried out continuously during drug development (Figure 1). 
When the drug enters clinical development, this evaluation is 
typically based on in vitro, animal, and in silico data, but the eval-
uation is rapidly strengthened by accumulating clinical data. If 
the drug is in later stages of clinical development or already on 
the market, DDI studies may be triggered by retrospective analy-
ses of population data, case reports, or additional in vitro data. 
Consequently, the drug of interest can be evaluated either as a 
substrate (victim drug), or as an inhibitor or inducer (perpetrator 
drug) of drug- metabolizing enzymes or transporters. For example, 
a retrospective epidemiologic analysis of the risk of rhabdomyoly-
sis in cerivastatin users with concomitant clopidogrel published in 
201211 triggered an investigation that resulted in identification of 
clopidogrel as an inhibitor of CYP2C8.12
There are multiple design issues and requirements that need 
to be carefully considered already when preparing a clinical DDI 
study protocol (Table 1). The golden standard for clinical DDI 
studies is a prospective crossover study, usually performed in 
healthy volunteers. The crossover design reduces the effect of in-
terindividual variability because individuals act as their own con-
trols. Furthermore, interindividual variability is reduced in healthy 
subjects who have normal kidney and liver function, are not using 
concomitant medication, and are devoid of other interfering 
factors (e.g., smoking). In a two- way pharmacokinetic crossover 
DDI study in healthy volunteers, sample sizes as low as 10–12 in-
dividuals are often sufficient to demonstrate clinically significant 
interaction, although a 2–3 times larger sample may be needed to 
demonstrate lack of DDI. In a crossover study, the washout period 
between study phases should be long enough to allow the drugs, 
metabolites, and their effects to be completely eliminated before 
the next phase, even when their elimination is impaired by strong 
inhibitors. When drug toxicity or adverse effects are an issue, DDI 
studies can be performed in patient populations, but they typi-
cally require a larger sample size due to greater variability caused 
by various individual factors, particularly if a parallel group design 
is used.
If inhibition or induction caused by a drug is investigated, a 
probe or index substrate for a specific pharmacokinetic pathway 
is typically used as the victim drug (Table 2). Particularly in drug 
development, such studies are first focused on the enzyme toward 
which the investigated drug is expected to cause the strongest inhi-
bition on the basis of in vitro inhibition data. If the DDI potential 
of a drug as an inhibitor is being studied, it should be administered 
preferably with multiple doses reaching and maintaining concentra-
tions approximating steadystate at the highest clinically used doses, 
so that the study could reveal the worst- case scenario (Figure 2). 
In addition, our recommendation is to use dose staggering, rather 
than simultaneous administration, to allow maximum inhibitor 
concentrations at the site of inhibition (e.g., an interval of 1 hour 
between the inhibitor and victim drug administration) to reveal 
the full extent of interaction, particularly if the absorption of the 
inhibitor can be delayed or if the victim is rapidly eliminated and 
Figure 1 Investigation of drug– drug interactions (DDIs). (a) Signals of a potential DDI may arise from a variety of sources. (b) Signals need 
careful assessment before further action is taken. (c) The golden standard for clinical DDI studies is a prospective crossover study with index 
drugs, usually performed in healthy volunteers. (d) The interpretation of the obtained results determines the (e) implications of the study.
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has extensive first- pass metabolism. On the other hand, to evalu-
ate induction effects, a sufficient multiple dosing period to reach 
near full induction should be used. However, when both induction 
and inhibition are possible, a delay between perpetrator and victim 
drug administration of, for example, 12 hours can be considered 
to ensure full induction effect of the perpetrator. For example, the 
prototypical CYP inducer rifampin13 inhibits OATP1B1/1B3 
immediately after dosing in vivo,14 but this effect is no longer pres-
ent after 12 hours.15
When the drug is investigated as a victim, probe or index in-
hibitors can be utilized to reveal the contributions of specific 
pathways to the drug’s pharmacokinetics (i.e., to document the 
clinical relevance of the key enzymes and transporters involved; 
Table 3). In this situation, a low single dose of the victim drug 
Table 1 List of recommended considerations and requirements of interventional DDI studies and examples of potential 
pitfalls in DDI studies and their interpretation
Typical requirements of a DDI study Potential pitfalls of DDI studies
General design issues
Healthy volunteers if no safety concerns Risky drugs given to healthy subjects
Patients if safety concerns or clinical focus Bias and confounding in observational patient studies
Crossover design Parallel group design may produce bias
Sufficient washout to eliminate carry- over effects Insufficient washout (e.g., a slowly eliminated  
metabolite still present)
Placebo control and blinding (e.g., in case of pharmacodynamic 
end points)
Dietary control/restrictions as necessary
Appropriate sample collection, storage and analytical method to 
cover > 80–90% of the AUC of the victim drug and metabolites
Inaccurate or insensitive analytical method, degradation  
of analytes during storage or analysis
Monitoring of perpetrator pharmacokinetics (compliance, 
quantification of exposure, presence after washout)
Perpetrator exposure not documented
Pharmacodynamic assessment Pharmacodynamic assessments neglected
DNA samples
Biomarker samples in selected cases
Necessary prior knowledge considered in design Deficiencies in preclinical and early clinical data  
(e.g., in mass- balance studies)
Safety issues
Strict exclusion criteria (e.g., contraindications, pregnancy) Careless exclusion criteria leading to risk  
of adverse effects
History, clinical examination, laboratory tests, and genotyping as 
necessary
Safety monitoring and sufficient follow- up Insufficient follow- up (residual drug effects)
Precautions and interventions to avoid adverse effects, even in 
the worst- case DDI scenario
Rescue interventions not prearranged
Blood sampling should generally not exceed the volume of blood 
donation
Perpetrator (inhibitor/inducer)
Selectivity and strength of index inhibitor (> 5- fold increase in 
AUC possible)
Suboptimal strength 
Nonselective inhibitor
Clinically relevant (high) dose depending on tolerability Too low dose, leading to weak inhibition
Dosing to reach and maintain steady- state, including time- 
dependent inhibition and induction
Clinically atypical dosing 
Duration of dosing too short/long to document maximal DDI
Victim substrate
Sensitivity of index substrate Lack of sensitivity (particularly if not considered in interpretation)
Documented selectivity of index substrate Lack of selectivity (particularly if not considered in interpretation)
High first- pass and short half- life preferable Long half- life victim with a short- acting or “presystemic” inhibitor
Monitoring a specific metabolic ratio can be useful
Dose, expecting the worst- case scenario Too high dose
Staggered dosing Victim drug administered too soon (or too long)  
after perpetrator to document maximal DDI
AUC, area under plasma concentration- time curve; DDI, drug– drug interaction.
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Table 2 Characteristics of possible index substrates of CYP enzymes
Enzyme Substrate Sensitivitya
Other relevant 
enzymes/transporters F t1/2 (h) Remarks E/F
b
CYP1A2 Agomelatine ++++ 0.05 1–2 Limited availability in some 
countries
Caffeined ++++ NAT, XO 1.00 3–7 E/F
Melatonin ++++ CYP1A1c 0.03 0.9
Theophylline ++ CYP3A4, CYP2E1 0.96 9 Adverse effects at high 
concentrations
E
Tizanidined ++++ 0.34 2.5 Adverse effects at high 
concentrations
F
CYP2B6 Bupropiond + 11β- HSD1c 0.9 11 Hydroxybupropion to bupropion 
AUC ratio is a selective and 
more sensitive marker of 
CYP2B6 than bupropion AUC
E
(S)- Ketamine ++ CYP3A4 0.08 2–6 Parenteral formulation can be 
given orally 
Efavirenz N/A 
(++)
CYP2A6 N/A 52–76 Limited DDI data E
CYP2C8 Amodiaquine N/A N/A 5 Limited DDI data 
Limited availability 
Metabolite t1/2 > 100 hours
E
Daprodustat ++++ N/A 1 Limited DDI data 
Limited availability, currently in 
phase III
Dasabuvird ++++ CYP3A4 0.70 5.5–6
Repaglinided +++ CYP3A4, OATP1B1 0.56 0.8 Adverse effects at high 
concentrations
E/F
CYP2C9 (S)- Warfarin ++ 
(+++)
0.93 
(racemic)
21–43 Bleeding risk E/F
Flurbiprofen ++ 0.92 5.5 4′- Hydroxyflurbiprofen/
flurbiprofen ratio is a sensitive 
marker of CYP2C9 
Limited availability of 
appropriate formulation 
Fluvastatind + 
(++)
OATP1B1 0.29 0.7
Tolbutamided ++ 
(+++)
0.8–0.9 5.9 Limited availability 
Adverse effects at high 
concentrations
E/F
CYP2C19 Lansoprazole ++ 
(+++)
CYP3A4 0.81 0.9 Delayed absorption F
Omeprazoled +++ 
(++++)
CYP3A4 0.53 0.7 Delayed absorption 
Inhibitor of CYP2C19
E/F
Pantoprazoled N/A 
(+++)
0.77 1.0 Delayed absorption 
Breath test established
Rabeprazole ++ 
(+++)
CYP3A4 0.52 1.5 Delayed absorption
CYP2D6 Desipramine +++ 
(+++)
CYP3A4 0.38 28 Limited availability in some 
countries
E/F
Dextromethorphand ++++ 
(++++)
CYP3A4 N/A 3.4 Dextrorphan/dextromethorphan 
ratio used as the index
F
Metoprolol ++ 
(+++)
CYP3A4 0.38 3.2 E
Nebivolol +++ 
(++++)
CYP2C19 N/A 11 F
Tolterodine ++++ 
(++++)
CYP3A4 0.26 
(NMs)
2.3 
(NMs)
(Continues)
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is usually sufficient. If a strong interaction is expected, even 
subtherapeutic victim drug doses may be necessary for ethical 
reasons to ensure a large enough safety margin in drug expo-
sure. Such a dosing scheme is adequately informative provided 
that the results can be extrapolated to steady- state conditions 
at clinically relevant doses (i.e., the victim drug displays linear 
dose- dependent and time- dependent pharmacokinetics). On 
the other hand, when the effect of a strong enzyme/ transporter 
inducer is investigated, a relatively high victim drug dose may 
be necessary to allow quantification of its concentrations. 
Monitoring of pharmacodynamic effects may be required for 
safety and can be useful when evaluating the clinical significance 
of the DDI. Pharmacodynamic end points are particularly use-
ful in cases where the victim drug has active metabolites, where 
organ specific disposition of the drug is anticipated to be altered 
(e.g., entry to the central nervous system via blood– brain bar-
rier), or where concomitant administration of the perpetrator 
and victim is anticipated to occur in clinical practice. If subjec-
tive pharmacodynamic measurements are used, double- blinding 
of the treatment phases is crucial.
Properties of suitable index substrates of drug-metabolizing 
enzymes
The most important property of an index substrate for DDI 
studies is sensitivity for the specific pharmacokinetic pathway 
investigated (Table 2). In the context of drug- metabolizing 
enzymes, the fraction metabolized by the enzyme should op-
timally be > 80%, so that an over fivefold increase in the area 
under plasma concentration- time curve (AUC) can occur when 
the enzyme is completely inhibited (Figure 2). Furthermore, 
other disposition mechanisms of the index substrate should be 
known in detail, especially in cases where the perpetrator has 
the potential to cause interactions via other mechanisms. The 
properties of the substrate should also be suitable for thorough 
characterization of its pharmacokinetic parameters in a clini-
cal study. Most importantly, the elimination half- life (t1/2) of 
the probe should be sufficiently short to avoid unnecessarily 
long sample collection (needed to cover 80–90% of its total 
AUC) and washout period. From this point of view, efavirenz, 
warfarin, and desipramine are far from ideal index substrates. 
Particularly if it is important to quantify a transient effect on 
enzyme activity, an index drug with extensive first- pass me-
tabolism and short t1/2 should be preferred. An optimal index 
substrate exhibits linear pharmacokinetics and has itself no ef-
fects on the pharmacokinetics of other drugs. Tolerability and 
lack of toxicity are also key issues, and the safety margin should 
be large enough to cover changes of several folds in exposure. 
Other desirable qualities for an index substrate include ease of 
quantification and availability of metabolite standards, as well 
as commercial availability at suitable doses. If equally good sub-
strates for the specific purposes are available, the choice should 
be made on the basis of the clinical relevance of the potential 
combinations.
There are several sensitive and selective index substrates for some 
CYP enzymes (e.g., CYP1A2, CYP2D6, and CYP3A), whereas 
sensitive index substrates for some CYPs (CYP2A6, CYP2B6, 
CYP2C9, and CYP2J2) are currently not available (Table 2). In 
some cases, sensitive index substrates are available, but they are 
also substrates for a transporter protein. For example, more than 
80% of repaglinide and simvastatin are metabolized by CYP2C8 
Enzyme Substrate Sensitivitya
Other relevant 
enzymes/transporters F t1/2 (h) Remarks E/F
b
CYP3A4 Buspirone ++++ 0.04 2.4 Sensitive to intestinal CYP3A4 
inhibition
Midazolamd ++++ 0.44 1.9 i.v. formulation available to 
assess hepatic CYP3A4 
Adverse effects at high 
concentrations
E/F
Sildenafil ++++ CYP2C9 0.38 2.4
Simvastatin 
(lactone)d
++++ < 0.05 2–3 Simvastatin acid substrate of 
OATP1B1 
Sensitive to intestinal CYP3A4 
inhibition
Triazolam ++++ 0.44 2.9 Adverse effects at high 
concentrations
F
The table contains all the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)-recommended index substrates and some selected 
alternatives based on potential advantages in sensitivity, selectivity, and/or relative safety. The data are compiled primarily from the UW Metabolism and 
Transport Drug Interaction Database (Copyright University of Washington 1999–2019. Accessed: January−February 2019), secondarily from drug labels.
AUC, area under plasma concentration- time curve; CYP, cytochrome P450; E/F, European Medicines Agency/US Food and Drug Administration; F, bioavailability; 
HSD- 1, hydroxysteroid dehydrogenase type 1; NAT, N- acetyl transferase; NMs, normal metabolizers; N/A, not available; OATP, organic anion-transporting 
polypeptide; t1/2, elimination half- life; XO, xanthine oxidase.
aIndication of sensitivity is based on data from a trial with an EMA/FDA- recommended index inhibitor of the affected CYP. In some cases, a second sensitivity 
value is given within brackets, based on pharmacogenetic data. Classification: ++++ a maximal > 10- fold increase in AUC, +++ a maximal 5–10- fold increase,  
++ a maximal two to fivefold increase, + a maximal 1.25−2- fold increase. Values for maximal fold increases in AUC are given in Table S1.
bIndicates if the drug is recommended as a clinical CYP probe substrate by the EMA (E) and/or the FDA (F) (2–3).
cBased on in vitro data only.
dOur recommended substrate.
Table 2 (Continued)
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and CYP3A, respectively, making them sensitive index substrates 
of these enzymes, but both are also fairly sensitive substrates of 
OATP1B1/1B3.16 The usefulness of both these drugs as index 
substrates has been documented extensively, and their nonselectiv-
ity can thus be taken into account when interpreting the results of 
the study. For non- CYP enzymes, knowledge is still evolving, and 
useful probe substrates are known only for few of them (Table 4). 
Lastly, if a sufficiently sensitive index substrate is not otherwise 
available or feasible, an alternative can be to use a specific reac-
tion (i.e., a metabolic ratio as an index of enzyme activity; see also 
Limited sampling strategies below).
Properties of suitable index inhibitors and inducers of drug-
metabolizing enzymes
In addition to safety, the two most important characteristics of 
index inhibitors are strength of inhibition and selectivity. The FDA 
and EMA guidances define a strong index inhibitor as a drug that 
increases the AUC of a sensitive index substrate of a given metabolic 
pathway more than or equal to fivefold,2,3 which equals at least an 
80% inhibition of clearance. Strong inhibition typically requires a 
repeated dosing of sufficient inhibitor doses for about five inhibitor 
half- lives before the victim drug is administered, followed by inhib-
itor dosing until victim AUC is fully characterized (Tables 1 and 
3, Figure 2). Strong inhibition increases the sensitivity to detect 
interaction effects, especially in cases where the victim drug is not 
solely dependent on the single elimination pathway. An optimal 
index inhibitor is selective (i.e., only inhibits one enzyme), so that 
direct mechanistic conclusions can be drawn from the result with 
reasonable confidence. On the other hand, if the index inhibitor 
inhibits several enzymes and/or transporters, the observed effects 
on victim drug pharmacokinetics cannot be attributed to a single 
pathway without further studies. Lastly, a long t1/2 of the inhibitor 
Figure 2 Design of drug– drug interaction (DDI) studies. (a) Effect of varying inhibitor dose (scenarios A-C) on the plasma concentrations of 
a substrate drug. A sufficient dose of the perpetrator drug is necessary to reach strong inhibition and to detect and accurately quantify a 
potential DDI. (b) Effect of a cytochrome P450 (CYP) inhibitor on the plasma concentrations of a substrate with varying fractions metabolized 
by the affected CYP (fm,CYP). In combination with a CYP inhibitor, a substrate drug with a low fm,CYP will give a smaller DDI than a sensitive 
substrate drug with a high fm,CYP. (c) Effect of dose staggering (scenarios A-D) on DDI magnitude. Strongest DDI can be detected when the 
victim drug is administered shortly after the inhibitor drug. (d) Effect of repeated dosing of perpetrator whose metabolite inhibits the CYP 
enzyme (scenarios A-C) on DDI magnitude. To study the worst- case scenario, the perpetrator should be dosed to steadystate and victim drug 
given at the time of the peak concentrations of the perpetrator. AUC, area under plasma concentration- time curve; od, once daily; sd, single 
dose.
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Table 3 Characteristics of possible index inhibitors of CYP enzymes
Enzyme Inhibitor Dose used in DDI trialsa Strengthb Also inhibits t1/2 (h) Remarks E/F
c
CYP1A2 Ciprofloxacine 500 mg b.i.d. +++ CYP3A4 3.3 Some safety concerns 
Enoxacin 400 mg b.i.d. +++ 3.3 Some safety concerns 
Limited availability
E
Fluvoxaminee 25 mg b.i.d. to 100 mg 
q.d.
++++ CYP2C19, CYP2D6, 
CYP3A4 
15 Strong CYP2C19 inhibitor F
CYP2B6 Ticlopidinee 250 mg b.i.d. + CYP2C19 98 Strong CYP2B6 inhibitor based on 
substrate metabolic ratio 
Strong CYP2C19 inhibitor 
MBI 
Limited availability 
Bleeding risk
E
CYP2C8 Clopidogrel 75 mg q.d. (first dose 
300 mg)
+++ CYP2B6, CYP2C19 6 Moderate CYP2C8 inhibitor with 
75 mg daily 
MBI (glucuronide) 
Bleeding risk
F
Gemfibrozile 600 mg b.i.d. ++++ OATP1B1, OAT3 1.1 MBI (glucuronide) E/F
CYP2C9 Fluconazolee 200 mg q.d. ++ CYP2C19, CYP3A4 32 Strong CYP2C19 inhibitor E/F
CYP2C19 Fluconazolee 200 mg q.d. +++ CYP2C9, CYP3A4 32
Fluoxetine 60 mg q.d. ++ CYP2D6 53 MBI 
Strong CYP2D6 inhibitor 
t½ of norfluoxetine 4–16 days
Fluvoxaminee 25 mg b.i.d. to 100 mg 
q.d.
+++ CYP1A2, CYP2D6, 
CYP3A4
15 Strong CYP1A2 inhibitor F
Omeprazolee 20–40 mg q.d. ++ 0.7 Strength based on nonsensitive 
probe substrates 
MBI
E
CYP2D6 Bupropion 150–300 mg q.d. +++ 11
Fluoxetine 60 mg q.d. ++++ CYP2C19 53 Strong CYP2C19 inhibitor 
t1/2 of norfluoxetine 4–16 days
E/F
Mirabegron 50 mg q.d. ++ 50 F
Paroxetinee 20 mg q.d. ++++ 17 MBI E/F
Quinidine 100 mg q.d., 100–
600 mg s.d.
++++ P- gp 6.2 Prolongs QT- interval E
Terbinafine 250 mg q.d. +++ CYP1A2 200–
400
CYP3A4 Clarithromycin 250–500 mg b.i.d. +++ CYP2C19, P- gp 3.3 MBI E/F
Cobicistate 150 mg q.d. ++++ CYP2D6, P- gp 5.2 MBI
Erythromycin 500 mg t.i.d. +++ P- gpd 1.6 MBI F
Fluconazole 200 mg q.d. ++ CYP2C19, CYP2C9 32 Strong CYP2C19 inhibitor F
Itraconazolee 100–200 mg q.d. ++++ CYP2J2,d P- gp 21 E/F
Ketoconazole 200 mg b.i.d. to 400 mg 
q.d.
++++ CYPC19, P- gp 3.3 Limited availability E
Posaconazole 300–400 mg b.i.d. +++ 31
Ritonavire 100–200 mg b.i.d. ++++ P- gp 4 MBI 
Induces CYP enzymes
E
Verapamil 80 mg t.i.d. to 240 mg q.d. ++ P- gp 4 MBI F
The table contains all the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) recommended index inhibitors and some selected 
alternatives based on potential advantages in sensitivity, selectivity, and/or relative safety. The data are compiled primarily from the UW Metabolism and 
Transport Drug Interaction Database (Copyright University of Washington 1999–2019. Accessed: January−February 2019), secondarily from drug labels.
CYP, cytochrome P450; DDI, drug– drug interaction; E/F, European Medicines Agency/US Food and Drug Administration; F, bioavailability; MBI, mechanism- based 
inhibition; OAT, organic anion transporter; P- gp, P- glycoprotein; s.d., single dose; t1/2, elimination half- life.
aTypical dose used in clinical DDI trials. Cocktail studies not included.
bIndication of strength is based on a trial with an index substrate of the affected CYP. Cocktail studies not included. Classification: ++++ a maximal > 10- fold 
increase in index substrate AUC, +++ a maximal 5–10- fold increase, ++ a maximal two to fivefold increase, + a maximal 1.25−2- fold increase. Values for 
maximal fold increases in AUC are given in Table S2.
cIndicates if the drug is recommended as a CYP probe inhibitor by EMA (E) and/or FDA (F) (2–3).
dErythromycin: based on in vitro data only. Itraconazole: based on interaction with astemizole.
eOur recommended inhibitor.
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makes it impractical in terms of the required washout period. For 
example, the t1/2 of 4–6 days of parent fluoxetine and 4–16 days of 
its metabolite norfluoxetine make fluoxetine a suboptimal index 
inhibitor of CYP2D6 in crossover studies. There are fairly good in-
hibitors for most CYP enzymes, but adequately documented strong 
and selective inhibitors for CYP2A6, CYP2B6, and CYP2C9 are 
missing (Table 3). For instance, high doses of fluconazole result 
in strong inhibition of CYP2C9, but they also cause a strong in-
hibition of CYP3A4 and CYP2C19. Likewise, suitable strong 
inhibitors for non- CYP enzymes are mainly lacking; for example, 
the strongest identified uridine 5′- diphosphate glucuronosyltrans-
ferase (UGT)- mediated DDIs are limited to a two to threefold in-
crease in AUC (Table 4). Therefore, studies with moderate, weak, 
and nonselective inhibitors are also needed in particular if concom-
itant clinical use is likely to occur frequently.
Unlike inhibition, induction of drug- metabolizing enzymes and 
transporters is usually highly nonselective, with few exceptions, 
such as induction of CYP1A2 by polycyclic aromatic hydrocarbon 
compounds.17 Of note, the inducibility of CYP2D6 by known 
drugs is low or negligible, even though its activity can be increased 
by certain conditions, such as pregnancy. Rifampin is the proto-
typical inducer that is most commonly used in clinical DDI stud-
ies because of its safety compared with other strong inducers, such 
as carbamazepine and phenytoin, and the strength of its inducing 
effect.13 Like other compounds causing pregnane X receptor- 
mediated induction, rifampin causes a particularly strong induc-
tion of intestinal and hepatic CYP3A but also induces many other 
drug- metabolizing enzymes and certain transporters. Thus, it can 
be used to test the sensitivity of a drug to strong enzyme induc-
tion. It should be noted that the CYP3A inducing effect of rifam-
pin is so strong that it can dramatically increase the fraction of the 
drug metabolized by CYP3A, so that even a drug that is normally 
mainly eliminated via noninducible or weakly inducible pathways 
becomes dependent on CYP3A4.
Specific considerations for transporter DDI studies
Current evidence indicates that of the numerous transporters, 
at least BCRP, OATP1B1, and P- glycoprotein (P- gp) mediate 
clinically relevant DDIs. In addition, multidrug and toxin ex-
trusion protein (MATE)1, MATE2- K, organic anion trans-
porter (OAT)1, OAT3, OATP1B3, OATP2B1, organic cation 
transporter (OCT)1, and OCT2 can be involved in DDIs.18 
Accordingly, drug transporters are routinely investigated already 
during preclinical drug development, providing a wealth of in-
formation regarding the properties of an investigational drug as 
a substrate and inhibitor of different transporters.19 With regard 
to clinical DDI studies, the FDA guidance instructs that the need 
of clinical transporter DDI studies of transporter substrates iden-
tified in in vitro studies should be considered on the basis of the 
drug’s site of action, route of elimination, likeliness of concomi-
tant use, and safety issues.2 For example, in the cases of P- gp and 
BCRP- mediated DDIs, most clinically relevant DDIs (aliskiren, 
dabigatran, digoxin, and fexofenadine as P- gp substrates, and 
rosuvastatin as a BCRP substrate) are based on inhibition of the 
absorption limiting effects of these transporters in the small intes-
tine or, in some cases, biliary or renal excretion.20–22 In addition, 
based on limited evidence, P- gp–mediated DDIs may also occur 
at blood–tissue barriers, such as the blood–brain barrier, warrant-
ing DDI studies if the site of pharmacological or toxic effects of a 
P- gp substrate drug is behind such a barrier. Moreover, for drugs 
targeting the liver or eliminated via the liver, current guidance 
states that DDI studies focusing on OATP1B1 or OATP1B3 can 
be warranted, and for drugs eliminated via renal excretion, studies 
on OAT1 or 3, OCT2, or MATE- mediated DDIs can be needed.2 
Recent studies support the roles of OCT1 and OATP2B1 in me-
diating hepatic and intestinal DDIs, indicating that they also need 
to be considered.19 Furthermore, if the drug is suspected to be a 
transporter inhibitor on the basis of in vitro data, clinical DDI 
studies could be conducted with likely concomitant substrate 
drugs that could be subject to a clinically relevant DDI, regardless 
of the suspected perpetrator’s own route of elimination.
DDI studies focusing on transporters have some challenges 
compared with drug- metabolizing enzymes. First, the lack of 
specific index substrates and inhibitors makes extrapolation of 
the results of DDI studies with other drugs challenging (Table 5, 
Table S3). For example, dabigatran etexilate could be used as a 
Table 4 Examples of DDIs involving non- CYP drug- metabolizing enzymes
Enzyme Victim Perpetrator (inhibitor) Consequence
Acylpeptide hydrolase Valproic acid glucuronide Carbapenems, e.g., 
meropenem
Decreased serum valproic acid levels92
COMT Levodopa Entacapone AUC 1.5- fold93
DPD 5- fluorouracil Sorivudine Fluoropyrimidine toxicity94
Monoamine oxidases (A and B) Dopamine Moclobemide Increased dopamine effects95
Thymidine phosphorylase Trifluridine Tipiracil AUC 37- fold96
UGT1A1 SN- 38 (irinotecan active 
metabolite)
Lopinavir- ritonavir AUC 3- fold97
UGT1A9 Dapagliflozin Mefenamic acid AUC 1.5- fold98
UGT2B7 Lamotrigine Valproic acid AUC up to 2-fold99
Xanthine oxidase 6- mercaptopurine Allopurinol AUC 5-fold100
AUC, area under plasma concentration- time curve; COMT, catechol- O- methyltransferase; CYP, cytochrome P450; DDI, drug– drug interaction; DPD, 
dihydropyrimidine dehydrogenase; UGT, uridine 5′- diphosphate glucuronosyltransferase.
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fairly specific P- gp substrate because its intestinal absorption is 
limited by P- gp, but dabigatran elimination is not dependent on 
renal P- gp and its sensitivity to P- gp inhibition at clinically used 
doses is only modest, so that even the strongest P- gp inhibitors 
have increased its AUC less than threefold.23 Similarly, recognized 
substrates of BCRP (e.g., rosuvastatin), OAT1/3 (e.g., adefovir, 
ganciclovir, and famotidine), and MATE or OCT2 transporters 
(e.g., dofetilide and metformin) have been at most moderately 
sensitive to inhibition of the respective transporters.24 In the cases 
of OATP1B1 and 1B3, there are some moderately sensitive sub-
strates, such as simvastatin (acid) and pitavastatin, but it is unclear 
if their AUC could be increased more than fivefold by inhibition 
of a single transporter only.
Well- established transporter inhibitors are typically either non-
selective or cause only limited extent of inhibition. Although pro-
benecid can be used as a relatively selective inhibitor of OATs 1 and 
3, P- gp inhibitors, such as clarithromycin, itraconazole, quinidine, 
and verapamil, also have inhibitory effects on CYP enzymes, and 
cyclosporine acts as a multitransporter inhibitor of BCRP, P- gp, 
and OATPs, and also inhibits CYP3A4. The OATP inhibitor ri-
fampin also acts as a strong inducer of drug- metabolizing enzymes. 
In the case of rifampin, the inducing effect can be largely avoided 
by using only a single rifampin dose, but this is primarily a relevant 
dosing scheme only in mechanistic DDI studies. In addition to the 
general lack of selectivity of transporter inhibitors, the strength 
of inhibition of many inhibitors may be limited, as it is unclear if 
any of the inhibitors have a sufficiently strong inhibitory effect on 
a single transporter to cause a more than fivefold increase in the 
AUC of a victim drug.
Second, modulation of transporter activity can result in changes 
in tissue distribution depending on the localization of the trans-
porter, without significant changes in plasma concentrations. 
Therefore, solely determining the plasma exposure of the victim 
drug might not be a valid end point for a transporter DDI study. 
In such cases, it can be useful to measure the pharmacodynamic 
effect of the victim drug to find out if the perpetrator caused any 
clinically relevant changes in drug concentration at the site of ac-
tion. A good example is metformin, which is not metabolized but 
whose absorption from the intestine, hepatic disposition, and renal 
elimination is subject to active transport. A DDI study design for 
metformin has been proposed, where the end points consist of sys-
temic pharmacokinetics, renal clearance, and antihyperglycemic 
effect.25 Another possibility to study tissue distribution of drugs is 
provided by nuclear imaging techniques, such as positron emission 
tomography and single-photon emission computed tomography, 
where the radiolabeled drug of interest is administered and non-
invasively measured.26
Pharmacogenetics
Our recommendation is to routinely collect DNA samples from 
participants of DDI studies and to genotype for well- characterized 
genetic variants of enzymes and transporters involved in phar-
macokinetics of investigated drugs. For example, in studies with 
index inhibitors or substrates of enzymes and transporters that 
exhibit common genetic variation, genotype information can be 
important in interpretation of the data, as genotype can mark-
edly influence the extent of the DDI.27 Genotype information 
may also be valuable in detecting causes for pharmacokinetic 
variability or outliers. In some cases, pharmacogenetic studies 
can also complement or replace DDI studies. They can be partic-
ularly useful if no selective or strong inhibitor is available, which 
is common with drug transporters and non- CYP enzymes. If 
the enzyme/transporter exhibits considerable genetic variability 
resulting in altered activity, especially loss- of- function, individu-
als with different genotypes can be studied in a genotype panel 
study to obtain clear mechanistic understanding of the impor-
tance of the specific pathway for the pharmacokinetics of the 
investigational drug. This type of study is only possible in cases 
where functionally relevant variants are known with suitable pop-
ulation frequencies, allowing recruitment of a sufficient number 
of subjects. For example, a common single-nucleotide variant in 
SLCO1B1 (c.521T>C, rs4149056), encoding the hepatic uptake 
transporter OATP1B1, results in decreased transport activity.16 
Thus, pharmacokinetics in heterozygous and homozygous vari-
ant allele carriers can be compared with that in reference allele 
carriers, to inform about the relevance of OATP1B1 in the dis-
position of the investigational drug, and its sensitivity to inhibi-
tion of OATP1B1. Of drug transporters and drug- metabolizing 
Table 5 Examples of transporter probe substrates and 
inhibitors for clinical DDI studies
Transporter Substrates Inhibitors
BCRP Rosuvastatin Cyclosporine
Sulfasalazine Eltrombopag
OATP1B1 or OATP1B3 Atorvastatin Cyclosporine
Pitavastatin Rifampin (single 
dose)
Pravastatin
Repaglinide
Rosuvastatin
Simvastatin (acid)
OATP2B1 Celiprolol Apple, orange and 
grapefruit juices 
(intestine)
OCT1 Sumatriptan N/A
Metformin
OCT2 Metformin Cimetidine
OAT1 Adefovir Pyrimethamine
Probenecid
OAT3 Benzylpenicillin Probenecid
P- gp Aliskiren Itraconazole
Dabigatran etexilate Verapamil
Digoxin
Fexofenadine
The data are compiled primarily from the University of Washington Metabolism 
and Transport Drug Interaction Database (Copyright University of Washington 
1999–2019. Accessed: February 2019). More information regarding the 
properties of substrates and inhibitors are given in Table S3.
BCRP, breast cancer resistance protein; DDI, drug–drug interaction; N/A, not 
available; OAT, organic anion transporter; OATP, organic anion-transporting 
polypeptide; OCT, organic cation transporter; P- gp, P- glycoprotein.
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enzymes, at least ABCG2, CES1, CYP2C9, CYP2C19, CYP2D6, 
CYP3A4, CYP3A5, DPYD, NAT2, SLC22A1, SLCO1B1, 
TPMT, UGT1A1, UGT1A3, UGT2B10, and UGT2B17 show 
significant genetic variability.28–30 Variants in these genes could 
be used to define subject groups in a genotype panel study and ge-
notyping for these genes should be considered if they are likely to 
be involved in the pharmacokinetics of the victim or perpetrator 
of a DDI study.
Index drug cocktails and microdosing
In the cocktail approach, more than one index substrate is ad-
ministered simultaneously to measure activities of several drug- 
metabolizing enzymes or transporters. In the context of DDI 
studies, this allows a drug to be studied as a perpetrator for several 
pharmacokinetic pathways in the same clinical study. A cocktail 
needs to be validated so that its components do not interact with 
each other, usually by administering each substrate separately and 
as a part of the cocktail.31 Recent advances in this area have oc-
curred in the utilization of very low doses of the substrate drugs 
(i.e., microdosing) and in the development of drug cocktails to 
assess drug transporter function.32 The use of microdosing is ben-
eficial in terms of safety and reduced likelihood of interactions be-
tween substrates. A potential problem is that it may be difficult to 
extrapolate the findings to clinically relevant doses if the substrate 
displays nonlinear pharmacokinetics.
Several phenotyping cocktails, including index substrates for dif-
ferent CYP enzymes, have been developed over the last 20 years.31 
Most of the proposed cocktails include index drugs for up to six 
CYP enzymes that have most commonly been CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, CYP2E1, and/or CYP3A4. The individual 
substrates are usually relatively selective for a single enzyme so that 
mechanistic conclusions can be drawn from the results. One of the 
challenges related to a few of the earlier cocktails is that some of the 
suggested index substrates are no longer commercially available in 
some countries. Two of the more recent cocktails called the Basel 
and Geneva cocktails, including substrates for CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4 (Geneva cocktail 
also including fexofenadine as an index for P- gp), have been specif-
ically validated for DDI studies.33–35
One of the biggest challenges in development of drug transporter 
cocktails is lack of selective index substrates. The first published 
cocktail approach for transporters included digoxin for P- gp, fu-
rosemide for OAT1 and OAT3, metformin for OCT2, MATE1, 
and MATE2- K, and rosuvastatin for OATP1B1, OATP1B3, and 
BCRP.36 The initial study showed mutual interaction resulting in 
higher rosuvastatin peak plasma concentration (Cmax) and AUC 
when administered as a part of the cocktail than individually. In 
further studies, the doses of furosemide and metformin were re-
duced, and a cocktail consisting of 0.25 mg digoxin, 1 mg furose-
mide, 10 mg metformin, and 10 mg rosuvastatin was shown to be 
devoid of mutual interactions.37,38 The sensitivity of the cocktail as 
well as the potential for mutual interactions in a situation where the 
exposure to one of the components is increased due to an inhibitor 
being studied, remains to be determined. Recently, a transporter 
cocktail utilizing microdosing was evaluated with known inhibi-
tors in DDI studies.39 The microdose cocktail consisted of 10 μg 
midazolam (CYP3A4), 375 μg dabigatran etexilate (P- gp), 10 μg 
pitavastatin (OATP1B), 25 μg rosuvastatin (BRCP, OATP, and P- 
gp), and 50 μg atorvastatin (OATP, BCRP, P- gp, and CYP3A4). 
In the DDI studies, the cocktail produced similar results as the 
index drugs had produced in previous studies, and only dabiga-
tran etexilate showed marked differences to clinical doses with an 
approximately twofold lower dose- normalized oral exposure and 
higher magnitude of interactions when microdosing was used.
Endogenous substrates
Instead of using index substrate drugs to assess the perpetrator’s 
impact on a specific pharmacokinetic pathway, an endogenous 
compound as a measure of activity of this pathway could be a 
useful alternative. The current status of endogenous biomarkers 
for DDI studies, their limitations, as well as strategies to investi-
gate novel biomarkers for this purpose has been reviewed in de-
tail recently.24,40–42 The main advantage of this approach is that 
it does not require the additional intervention of administering 
the index substrate. This could be especially useful during early 
clinical drug development, or when the perpetrator cannot be 
administered to healthy volunteers due to safety concerns. The 
endogenous biomarker needs to be validated to fit this purpose, 
it should be selective for the enzyme or transporter under inves-
tigation, and it should not be altered by disease states or dietary 
factors. Well- validated endogenous biomarkers that could func-
tion as an alternative to formal DDI studies are, however, still 
lacking. For example, 4β- hydroxycholesterol, 6β- hydroxycortisol, 
and 6β- hydroxycortisone could be used as sensitive biomarkers of 
CYP3A activity, unconjugated bilirubin as a nonselective marker 
of UGT1A1, and coproporphyrin as a marker of OATP1B1/1B3, 
but they are only suitable in initial characterization of DDI risks.41
Limited sampling strategies and population pharmacokinetic 
modeling
In a stand- alone DDI study, the pharmacokinetic profile of the 
victim drug should be fully characterized with a suitably frequent 
and long sampling schedule, so that the extrapolated part of the 
total AUC is < 20%.2 In contrast to studies in healthy volunteers, 
rich sampling strategy is usually not feasible in large patient pop-
ulations. However, population pharmacokinetic analyses can be 
useful to assess the clinical impact of concomitant medications 
on the pharmacokinetics of the drug of interest despite sparse or 
limited sampling. The strength of such studies is that DDIs can be 
investigated in the clinically relevant patient group using typical 
doses on long- term basis and that the effects of frequently copre-
scribed drugs can be studied irrespective of prior knowledge on 
relevant DDI mechanisms. To make the best use of population 
pharmacokinetic data, the study protocol, including sampling 
strategy, should be carefully designed before commencing data 
collection. In particular, accurate documentation of the dosage 
and timing of drug administration, as well as sampling times, is 
essential. This is especially important for drugs with variable ab-
sorption rate and short t1/2. Ideally, also perpetrator drug exposure 
should be documented by using available samples. The methodol-
ogy and design of DDI studies using population pharmacokinetic 
analyses is discussed in a recent commentary by the International 
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Society of Pharmacometrics Working Group.43 For example, a 
simulation case study with methotrexate and trastuzumab has 
shown that, with careful design, population pharmacokinetic 
studies can be a viable alternative to DDI studies.44
Another instance where limited sampling can be used is with 
index substrate drugs whose validated metrics of enzyme activity 
is based on only few or single sample time points, typically by cal-
culating a metabolic ratio from the parent drug and its metabolite, 
whose formation is selective for the enzyme in question. The in-
terpretation of such indices should be done cautiously particularly 
if the fate of the metabolite is subject to changes by perpetrators. 
In an ideal case of a fully specific index ratio, a decrease of 80% 
in a metabolic ratio indicates a maximal increase of fivefold in the 
AUC of a sensitive substrate drug. Furthermore, limited sampling 
can be subject to large variability due to, for example, delayed drug 
absorption, especially if the metric is based on the parent drug 
concentration only. For example, limited sampling strategies for 
midazolam and warfarin have shown poor correlation with full 
pharmacokinetic profiling.45,46 On the other hand, determination 
of a metabolic ratio from a single time point can be a more useful 
metric that accurately reflects the systemic clearance of the drug. A 
good example of such a metric is caffeine, which is selectively me-
tabolized by CYP1A2 to paraxanthine. The paraxanthine/caffeine 
ratio from a single plasma sample, taken 4–6 hours after caffeine 
intake, can be used to assess CYP1A2 activity.47 Such single time 
point metabolic ratios have been tested in index drug cocktails as 
well.34,48 In cocktail approaches, however, a single sampling time 
represents a compromise between the different substrates and 
might not be optimal for each index substrate.
One approach to limit blood sample volumes and to make blood 
sampling more feasible is to use capillary blood microsamples and 
dried blood as the sample matrix.34 The main advantage of this ap-
proach is its low invasiveness and the flexibility it potentially offers, 
such as applicability in low resource environments or self- sampling 
by the study participants. However, the measurement of whole-
blood concentrations in this matrix needs to be validated against 
samples collected by venipuncture, and whole blood concentra-
tions of drugs often differ from those in plasma/serum. Use of 
dried blood samples can be very useful in large- scale studies, such 
as phase III trials or in studies in vulnerable populations, such as 
children, typically in conjunction with limited sampling strategies, 
but its usefulness for formal DDI studies in healthy volunteers is 
limited.
Physiologically-based pharmacokinetic modeling
In the past 2 decades, major advances have been made in the mod-
eling methods used for prediction of DDIs on the basis of in vitro 
CYP inhibition data.49,50 In particular, physiologically-based 
pharmacokinetic (PBPK) modeling, a dynamic approach incorpo-
rating changes in drug concentrations over time, has evolved and 
is becoming increasingly used even for regulatory decisions.8,51,52 
PBPK models simulate concentration- time profiles of drugs in 
plasma and/or an organ of interest, and allow for simultaneous 
modeling of multiple drug disposition processes, providing a 
range of opportunities.53,54 The reliability of PBPK models in-
creases with accumulating clinical data and information on the 
 disposition/elimination pathways of the drugs and their metabo-
lites. In the ideal case, the model can be cross- verified using data 
from multiple clinical studies concerning both the perpetrator 
and the victim drug.
PBPK DDI modeling is encouraged by regulatory agencies,2,3 
and the pharmaceutical industry is increasingly using PBPK 
modeling to predict DDIs and related dosing decisions as re-
placement for clinical studies.8 Examples of submissions where 
clinical DDI studies have been waived on the basis of PBPK 
DDI simulations include drugs such as cobimetinib, lesinurad, 
and olaparib.55 In regulatory submissions, PBPK DDI modeling 
has been applied to (i) predict DDIs with perpetrator/victim 
drugs other than those used in clinical studies, (ii) predict DDIs 
in various subpopulations (e.g., specific patient populations or 
populations with genetically different CYP activities), (iii) pre-
dict the effects of altered dosing regimens/repeated dosing of 
perpetrator/victim drug, (iv) predict the effects of pH modu-
lation on drug solubility/absorption, and (v) predict the effects 
of a perpetrator drug on single drug enzymes/transporters.55 In 
addition, PBPK DDI modeling has been applied to support the 
design of clinical DDI studies, and mechanistically explain clin-
ically observed DDIs.
There are many examples of successful PBPK DDI models, 
in particular in cases where the interaction is based on simple 
reversible CYP inhibition. In contrast, modeling of the effects 
of combined time- dependent inhibition and reversible inhi-
bition, or time- dependent inhibition and induction are not as 
established.56,57 Moreover, modeling of DDIs affecting non- 
CYP drug- metabolizing enzymes and drug transporters may be 
difficult due to lack of selective in vivo data, and uncertainties 
concerning the expression levels and turnover characteristics 
of transporters and enzymes, as well as scaling of drug concen-
tration levels at the relevant cellular or subcellular sites.55,57,58 
A good example highlighting the challenges with modeling of 
transporter- DDIs, is related to OATP1B1- mediated influx of 
drugs to hepatocytes. The measured in vitro OATP1B1 Ki val-
ues of clarithromycin, clopidogrel acyl- β- D glucuronide, cyclo-
sporine, and rifampin do not seem to be low enough to recover 
DDIs observed in clinical studies, which has forced modelers 
to adjust OATP1B1 inhibition constant values in PBPK mod-
els against measured values.59–61 A possible explanation of this 
disconnect from physiological principles is time- dependent in-
hibition of OATP1B1 by these inhibitors and interplay between 
drug transporters and drug- metabolizing enzymes.62 It is ob-
vious that the biochemical and physiological processes related 
to transporter- mediated DDIs are not fully understood, which 
poses one of the biggest challenges to development of PBPK 
modeling and in vitro–in vivo predictions in general.
Overall, PBPK modeling is a useful tool for DDI research to 
be used in concert with clinical DDI studies. However, the cur-
rent limitations of PBPK modeling in complex situations, where 
multiple mechanisms and DDIs are involved, should be taken 
into account. On the whole, there has been a lack of consistency 
in model development and quality assessment practices, demon-
strating a need for best- practice guidelines, as well as for har-
monization of guidelines between regulatory agencies.49,55 At 
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present, however, PBPK models can be highly valuable in inter-
pretation and extrapolation of clinical DDI studies to different 
clinical situations, as well as in planning and design of further 
clinical studies.
COMPLEX DDIS
Although DDIs based on a single well- defined pharmacoki-
netic mechanism can already be predicted and extrapolated to 
different clinical situations with great confidence, it has become 
increasingly recognized that pharmacokinetic interaction mech-
anisms are often complex.50,63,64 Complex DDIs can be difficult 
to anticipate and control, and can pose a big challenge during 
early drug development. From the drug development perspective, 
as well as from the clinical point of view, some of the most prob-
lematic complex mechanisms are those involving autoinhibition 
or induction of the drug’s own metabolism, the possibility of sev-
eral simultaneous mechanisms, inhibition, or induction by major 
drug metabolites and time- dependent inhibition.64 Although 
comprehensive preclinical data and modeling approaches are fun-
damental for understanding such DDIs, clinical DDI studies are 
eventually indispensable to understand their clinical relevance.
For example, on the basis of modern preclinical research meth-
ods, autoinduction and autoinhibition can be suspected early, 
but only the first clinical pharmacokinetic studies reveal if they 
are clinically relevant. In the worst case, autoinduction can be so 
strong that adequate drug exposure cannot be obtained despite 
extreme doses and the drug development program fails. On the 
other hand, both autoinduction and autoinhibition can result in 
dose- dependent and time- dependent changes in the relative im-
portance of different disposition pathways and thereby alter the 
sensitivity of the drug to inhibitory perpetrators. For example, 
the tyrosine kinase inhibitor imatinib is a mechanism- based in-
hibitor of CYP3A465 that can increase the plasma concentrations 
of CYP3A4 substrates, such as simvastatin. As CYP3A4 plays an 
important role in the metabolism of imatinib, the CYP3A4 inhib-
itory effect can lead to a complicated increase in the significance of 
the alternative elimination pathway (CYP2C8), and an increased 
risk of increased imatinib levels due to CYP2C8 inhibitors during 
multiple imatinib dosing.66
An even more complex drug is the kinase inhibitor midostau-
rin (Figure 3), which is a substrate, time- dependent inhibitor and 
inducer of CYP3A4.67–69 Based on mechanistic information, it is 
conceivable that midostaurin could cause a temporary net (auto)
inhibition of CYP3A4, which gradually changes to net (auto)in-
duction. On the basis of a short study with midazolam as a victim 
drug, the effect of midostaurin on CYP3A4 could be interpreted 
as negligible.67 However, a DDI study carried out at two early 
time points may not have revealed a temporary inhibition in the 
beginning of treatment and leaves unclear if midostaurin acts as 
an inducer decreasing concentrations of CYP3A4 substrates in 
long- term treatment. In addition, the sensitivity of single- dose 
midostaurin to CYP3A4 inhibition may not have revealed its full 
sensitivity to CYP3A4 inhibition at steady state (i.e., after auto-
induction has increased the role of CYP3A4 in its metabolism). 
Deciphering this kind of dose- dependent and time- dependent 
complexity requires clinical DDI studies where the drug is the per-
petrator, as well as studies where the drug is the victim. Moreover, 
clinical DDI studies at different time points during the course of 
treatment are needed, as PBPK models are not reliable in this area, 
particularly because there is paucity of clinical data on the dose and 
time dependency of DDIs involving drugs with nonlinear phar-
macokinetics, and because enzyme- specificity of induction is not 
thoroughly understood.
Examples of DDIs involving multiple mechanisms simultane-
ously (i.e., DDIs where a multipathway substrate is given simulta-
neously with an inhibitor and/or inducer of the same pathways), 
Figure 3 Pharmacokinetics and drug– drug interactions of midostaurin. (a) Midostaurin exhibits time- dependent pharmacokinetics, with 
increasing trough plasma concentrations during the first 3–6 days of therapy, followed by a 60–70% decline in concentrations until a steady 
state is reached.68,69 Autoinduction of cytochrome P450 (CYP)3A4 by midostaurin and its two major metabolites is thought to be involved in 
the time- dependent pharmacokinetics of midostaurin.69 (b) Midostaurin is a sensitive CYP3A4 substrate, and ketoconazole has increased its 
SD area under plasma concentration- time curve (AUC) by more than tenfold.67 (c) Although both midostaurin and its two major metabolites 
are inducers and mechanism- based inhibitors of CYP3A4 in vitro, the drug has had no effect on midazolam pharmacokinetics in healthy 
subjects, following either a single midostaurin dose (100 mg) or 2 days after the last dose of multiple midostaurin doses (50 mg twice daily 
for 3 days).67 Clinical data shown are from refs. 67 and 68. d, day; od, once daily; sd, single dose; tid, three times daily.
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include the gemfibrozil- repaglinide (OATP1B1/1B3 and CYP2C8 
inhibition), cyclosporine- rosuvastatin (OATP1B and BCRP inhi-
bition), sofosbuvir/velpatasvir/voxilaprevir- rosuvastatin (inhibi-
tion of OATP1B1/1B3 and BCRP), and many ritonavir- victim 
drug (P- gp and CYP3A4 inhibition and CYP induction) interac-
tions.70–73 The key to building an understanding of this kind of 
DDI risk is to first learn with enzyme and transporter selective 
preclinical and clinical studies, which specific enzymes and trans-
porters are involved in the drug’s metabolism and disposition and 
which are inhibited or induced by the drug. Thereafter, relevant 
DDIs with potential for multiple mechanisms simultaneously can 
be studied clinically using standard methods. If additional mecha-
nistic understanding is needed, studies with multiple perpetrators 
or different inhibitor dosing or timing experiments may be useful.
What comes to other types of complex DDIs, those caused by 
inhibitory or inducing major metabolites and mechanism- based 
inhibition typically require carefully performed in vitro studies 
to initially identify the risks. The contribution of metabolites as 
perpetrators has only been realized during the past decade. It has, 
for example, been estimated that the clinically observed CYP2C9 
inhibition by amiodarone, CYP2D6 inhibition by bupropion, and 
CYP3A4 inhibition by sertraline could only be explained accu-
rately when considering their inhibitory metabolites.74 Of note, 
even glucuronide metabolites can act as mechanism- based inhib-
itors of CYP enzymes, capable of causing strong DDIs.75 Such 
DDIs can usually be studied using standard clinical DDI study 
methodology, although in the case of mechanism- based inhibition 
and in the case of metabolites that have a very long t1/2, the time- 
dependency of the DDI risk may warrant long- term administration 
or other more focused studies. In addition, the growing number 
of fixed- dose combination products among newly marketed drugs 
(especially antiviral agents) represents a unique challenge of under-
standing the contribution of each drug component to the overall 
clinical effect when the combination is evaluated as a perpetrator.
From a clinical point of view, involvement of multiple perpe-
trator drugs simultaneously, and the influence of genetic vari-
ants or disease states on the risk of DDIs76 often necessitate 
specific DDI studies. For example, concomitant treatment with 
a CYP2C8 inhibitor (e.g., gemfibrozil) and a CYP3A4 inhib-
itor (e.g., itraconazole) can lead to an extremely strong effect 
on the pharmacokinetics of drugs that are substrates for both 
these enzymes, such as repaglinide and loperamide.71,77 In case 
of genetic variants, poor metabolizer individuals are typically 
insensitive to inhibition of the genetically deficient enzyme, 
such as inhibition of CYP2C19 by omeprazole or inhibition of 
CYP2D6 by paroxetine,78,79 but they may be particularly suscep-
tible to DDIs mediated by inhibition of an alternative pathway, 
such as CYP3A4. Genetic variants leading to increased activ-
ity usually have an opposite effect. On the other hand, genetic 
variants can also influence the concentrations of the perpetra-
tor drug, such as the CYP2C19 substrate voriconazole, thereby 
modifying the extent of inhibition/induction.80 Moreover, for 
example, fluvoxamine inhibited the oral clearance of theophyl-
line by 62% in healthy subjects but only by 12% in patients with 
severe cirrhosis, indicating that patients with severe cirrhosis are 
not susceptible to this DDI.81 The conduct of clinical studies 
on these types of complex DDIs is based on the characteristics 
of the victim drug (i.e., which enzymes and transporters are rel-
evant to the drug). Such studies typically require a larger clin-
ical study, which includes an adequate number of subjects in 
each genotype or disease group, or a multiphase crossover study, 
where different perpetrators and perpetrator combinations can 
be compared. The study designs are relatively straightforward, 
but the recruitment of a sufficient number of individuals with a 
rare genotype or rare disease may be challenging.
PITFALLS AND INTERPRETATION OF DDI STUDIES
Pitfalls
There are multiple potential pitfalls in the design and conduct 
of DDI studies that can lead to inaccurate results, ethical prob-
lems, false alerts, or, in the worst case, failure to identify relevant 
DDI risks (Table 1). Particularly, deficiencies in preclinical data 
or lack of understanding of the importance of specific pharma-
cokinetic pathways have led to failures to identify clinically haz-
ardous DDIs. The past cases that have led to market withdrawals, 
such as those of cerivastatin, cisapride, and terfenadine as victims 
and sorivudine as a perpetrator, have been caused mainly by fail-
ure to understand basic mechanistic issues, together with dose- 
dependent toxicity of the victim drugs.82 In the following, we 
are not presenting an exhaustive review of all possible pitfalls but 
instead describe three case examples of pitfalls that can lead to in-
appropriate conclusions of the DDI risk.
In the late 1990s, the importance of CYP2C8 in drug metabo-
lism was not understood. Eventually, the gemfibrozil- cerivastatin 
interaction revealed the potential significance of the enzyme after a 
series of in vitro and clinical studies that were needed to understand 
the mechanisms of this DDI.83 Initially, cerivastatin was brought to 
the market with arguments of a favorable interaction potential due 
to metabolism by both CYP3A4 and CYP2C8. However, it was 
shortly thereafter withdrawn from the market in 2001 owing to 
multiple cases of rhabdomyolysis. In about half of the cases, the pa-
tients had been using gemfibrozil and cerivastatin concomitantly, 
and, sadly, many of the cases had a fatal outcome. Soon, gemfibrozil 
was shown to increase the AUC of cerivastatin five to sixfold and 
to greatly reduce the formation of its CYP2C8- dependent M- 23 
metabolite, whereas strong CYP3A4 inhibition by itraconazole 
had only a minor effect on cerivastatin exposure.84,85 At first, gem-
fibrozil was identified as a rather modest and nonselective inhibi-
tor of CYP2C8 in vitro, and it was only later discovered that the 
main metabolite of gemfibrozil, gemfibrozil 1- O- β- glucuronide, 
is a strong mechanism- based inhibitor of CYP2C8.86 This case 
concretely illustrated that it is difficult to anticipate DDIs without 
systematic studies and thorough understanding of the DDI charac-
teristics of both the victim and perpetrator drugs.
The cyclooxygenase- 2 selective nonsteroidal anti- inflammatory 
drug rofecoxib was initially considered to be a modest inhibitor of 
CYP1A2. This information in the labeling was mainly based on a 
DDI study using theophylline as a CYP1A2 index substrate, where 
rofecoxib 25 mg once daily increased the AUC of theophylline 
only 1.5- fold.87 However, a DDI study with a similar design using 
tizanidine as a probe substrate resulted in a 13.6- fold increase in its 
AUC, indicating strong CYP1A2 inhibition by rofecoxib.88 The 
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reason for this apparent discrepancy is theophylline’s lack of sen-
sitivity as an in vivo index substrate of CYP1A2, partly due to its 
high bioavailability and lack of first- pass metabolism. At the time, 
in vitro data regarding the effect of rofecoxib on CYP1A2 were 
also lacking, and it was only later shown that rofecoxib is a potent, 
mechanism- based inhibitor of CYP1A2.89
As demonstrated in Figure 2, the inhibitor dose and timing of 
the substrate in relation to inhibitor administration can greatly 
affect the magnitude of the observed interaction. An example of 
this is provided by examining drug interaction studies involving 
the intestinal CYP3A inhibitor grapefruit juice and the CYP3A 
substrate lovastatin. In the study by Rogers et al.,90 grapefruit juice 
was administered for 4 days in the morning and 40 mg lovastatin 
was administered in the evening of day 3. Grapefruit juice in-
creased the AUC of lovastatin 1.9- fold and that of lovastatin acid 
1.6- fold only. It is notable that the exact dosing interval between 
the perpetrator and victim is not given in the paper. The results are 
in contrast with an earlier study by Kantola et al.,91 where grape-
fruit juice increased the AUC values of lovastatin and lovastatin 
acid by 15- fold and 5- fold, respectively. In this study, grapefruit 
juice was administered thrice daily for 2 days, and lovastatin was 
administered simultaneously with grapefruit juice on day 3, fol-
lowed by additional grapefruit juice doses 0.5 and 1.5 hours after 
lovastatin. Even though this amount of grapefruit juice intake is 
not likely to occur frequently in real life, the results represent a 
potential worst- case scenario of the grapefruit juice- lovastatin in-
teraction. This example also makes evident how important it is to 
consider the study design both when planning and interpreting 
the results of a DDI study.
During the past 2 decades, DDI guidelines have been frequently 
updated by the regulatory authorities, and most serious pitfalls can 
now be avoided by following the guidelines. However, knowledge 
on non- CYP enzyme- mediated metabolism and transporters still 
continues to emerge, and is going to further improve DDI study 
methodology and the predictability of DDIs. Yet, it is still difficult 
to evaluate the quantitative roles of all relevant disposition path-
ways of a drug based on in vitro data. Consequently, a potentially 
dangerous pitfall is to use PBPK modeling in situations where its 
reliability without additional clinical data is questionable (e.g., in 
the case of complex DDIs, as outlined above).
Interpretation and extrapolation of findings
It is usually fairly straightforward to interpret the findings of stan-
dard DDI studies with index inhibitors or index substrates and 
to classify the tested drug’s sensitivity to inhibition of a specific 
pathway or its strength as an inhibitor or inducer of a transporter 
or enzyme. Key issues to consider when interpreting DDI data are 
the strength and selectivity of the index perpetrator at the given 
dose and the sensitivity of the index substrate, as well as the gen-
eral design of the study, including the dose and time relationships 
(Figure 2). For example, if the index drug is not sensitive enough, 
even full inhibition of a single metabolic pathway does not pro-
duce an over fivefold AUC change that would classify the perpe-
trator drug as a strong inhibitor.
When it comes to interpretation of complex situations 
and extrapolation of the findings with other scenarios, PBPK 
modeling can be highly valuable. Yet, if multiple mechanisms 
are involved in the DDI, such as involvement of both transport-
ers and metabolism, or simultaneous induction and inhibition, 
extrapolation of the findings with other dosing scenarios or dif-
ferent drugs should be done with caution. In cases where a single 
mechanism (e.g., CYP3A4 inhibition) is crucial, extrapolation 
of the findings with other scenarios can be made with more 
confidence. It should be emphasized, however, that a very sen-
sitive but nonselective index substrate due to combined roles of 
metabolism and transport can be superior to a poorly sensitive 
index substrate when the purpose is to detect a DDI risk. On 
the other hand, when the clinical significance of a DDI is eval-
uated, also complex issues, such as multiple simultaneous mech-
anisms, time- dependency and dose- dependency of transporter/
enzyme inhibition and induction, as well as time- dependent 
and dose- dependent pharmacokinetics of the victim drug, often 
need to be considered in interpretation and extrapolation of 
the findings. As highlighted by the midostaurin and imatinib 
cases above, the sensitivity of a victim drug to DDIs may be al-
tered by time- dependent changes in its own pharmacokinetics. 
Moreover, the magnitude of DDIs occurring during the absorp-
tion and first- pass metabolism of the victim may depend on 
the dosing interval between the perpetrator and victim, which 
should be considered in the interpretation (e.g., using PBPK 
modeling).
CONCLUSION
Evaluation of the DDI potential of drugs under development 
and on the market is a crucial issue for drug safety. Advances in 
in vitro methodology and modeling methods have greatly ad-
vanced our understanding of molecular mechanisms of DDIs 
and the ways to predict and interpret them. Clinical DDI stud-
ies remain, however, an integral part of the process of evaluat-
ing the DDI risks. Moreover, clinical DDI studies have revealed 
previously unknown DDIs and shed light on their mechanisms, 
which have then been confirmed by, for example, in vitro stud-
ies through reverse translation. As clinical DDI studies may not 
cover every single permutation of various parameters affecting 
the outcome, mechanistically focused clinical studies in concert 
with in silico models have great synergy in providing compre-
hensive understanding of DDIs and their clinical relevance. In 
conclusion, there is no optimal way to study DDIs, but the de-
sign of every study needs to be based on careful evaluation of 
the available data, to ensure safety and maximal usefulness of 
the study.
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